In a 72‑year‑old patient with Lewy body disease who has been taking quetiapine 25–50 mg daily for three weeks, should the medication be discontinued or tapered, and what alternative sleep aid is recommended?

Discontinue Quetiapine Immediately in This 72-Year-Old Patient with Lewy Body Disease

Quetiapine should be discontinued in this patient with Lewy body disease, as antipsychotics—including low-dose quetiapine—carry an increased risk of death in elderly populations with dementia-related psychosis and lack evidence for efficacy in treating insomnia. 1, 2

Why Quetiapine Must Be Stopped

Critical Safety Concerns in Lewy Body Disease

The FDA drug label for quetiapine explicitly warns that all antipsychotics, including low-dose quetiapine, are known to cause harms, including increased risk for death in elderly populations with dementia-related psychosis 2. This is particularly concerning in Lewy body disease, where patients demonstrate neuroleptic sensitivity—meaning they experience worsened motor symptoms, cognitive decline, and potentially life-threatening complications even at low doses 3.

Recent 2025 data demonstrates that low-dose quetiapine for insomnia in older adults is associated with:

• 3.1-fold increased mortality risk compared to trazodone (HR 3.1,95% CI 1.2-8.1)
• 8.1-fold increased dementia risk compared to trazodone (HR 8.1,95% CI 4.1-15.8)
• 2.8-fold increased fall risk compared to trazodone (HR 2.8,95% CI 1.4-5.3) 4

Lack of Evidence for Insomnia

The 2020 VA/DoD guidelines explicitly state: "Antipsychotics, most commonly quetiapine, have been used to treat insomnia disorder, but the evidence supporting their use is sparse and unclear, with small sample sizes and short treatment durations, thus making any determination of efficacy inconclusive." 1 The guidelines advise against use of antipsychotics for chronic insomnia disorder 1.

How to Discontinue Quetiapine

Tapering Protocol

After three weeks of use at 25-50 mg daily, gradual tapering over 1-2 weeks is appropriate to minimize rebound insomnia and potential withdrawal effects 5:

• Week 1: Reduce to 25 mg every other night (if currently on 50 mg) or 12.5 mg nightly (if on 25 mg)
• Week 2: Discontinue completely

The relatively short duration of use (3 weeks) and low dose make rapid discontinuation safer than in long-term users, but some tapering reduces rebound effects 5.

Alternative Sleep Aid Recommendations

First-Line: Low-Dose Doxepin

Low-dose doxepin (3-6 mg at bedtime) is the preferred pharmacological alternative for this patient 1. This recommendation is based on:

• FDA approval specifically for insomnia
• Evidence of efficacy in sleep maintenance
• Lower risk profile compared to other sedating medications
• No black box warning for use in elderly patients with dementia (unlike antipsychotics)

The 2020 VA/DoD guidelines found statistically significant improvements in sleep outcomes with low-dose doxepin, though adverse event rates increased with longer treatment 1.

Second-Line: Nonbenzodiazepine BZRAs

If low-dose doxepin is ineffective or not tolerated, consider nonbenzodiazepine benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) at the lowest effective dose 1:

• Start with zolpidem 5 mg (lower dose for elderly) at bedtime
• Use for the shortest possible duration
• Counsel on risks of sleep behaviors (sleepwalking, sleep driving)

However, these agents should be used cautiously given fall risk and cognitive effects in elderly patients.

Avoid These Alternatives

Do NOT use the following in this patient:

• Trazodone: Despite common use, evidence shows no difference in sleep efficiency versus placebo, with adverse effects outweighing limited benefits 1
• Benzodiazepines: Unacceptable risk of falls, cognitive impairment, and dependency in elderly patients 1
• Antihistamines: Strong recommendation to avoid in older adults per 2019 Beers Criteria due to antimuscarinic effects; tolerance develops after 3-4 days 1
• Other antipsychotics: All carry similar or worse risks than quetiapine in Lewy body disease

Critical Monitoring After Discontinuation

Watch for Neuroleptic Sensitivity Resolution

After stopping quetiapine, monitor for:

• Improvement in motor symptoms (rigidity, tremor, bradykinesia) over 1-2 weeks
• Cognitive function stabilization or improvement
• Resolution of any orthostatic hypotension or sedation

One case report documented complete return to baseline motor and cognitive function within one month of discontinuing olanzapine in a patient with Lewy body dementia 3.

Rebound Insomnia Management

Expect potential rebound insomnia for 1-3 days after discontinuation 5. Manage with:

• Sleep hygiene education
• Cognitive-behavioral therapy for insomnia (CBT-I) if available
• Temporary use of low-dose doxepin as bridge therapy

Special Considerations for Lewy Body Disease

If Psychosis Develops

If the patient develops hallucinations or delusions (common in Lewy body disease), pimavanserin is the preferred agent 3, 6:

• FDA-approved for Parkinson's disease psychosis
• No dopamine receptor antagonism, thus no motor worsening
• Safer profile in Lewy body disease compared to traditional antipsychotics

Quetiapine, despite being considered "safer" among antipsychotics for Parkinson's disease, still carries significant risks and should only be considered if pimavanserin fails and psychosis is severe 7, 8, 6.

Acetylcholinesterase Inhibitors

Consider rivastigmine or donepezil for cognitive and psychiatric symptoms in Lewy body disease, as meta-analysis shows beneficial effects 9, 6. These may indirectly improve sleep quality by reducing nocturnal confusion and hallucinations.